

Selected Pharmaceuticals in Development as of July 19, 2022



Cardiovascular and Metabolism

XARELTO (rivaroxaban)
COVID-19 MI (PREVENT-HD)

AAV-CNGB3
Achromatopsia

AAV-CNGA3
Achromatopsia

AAV-RPGR
Retinitis Pigmentosa

Milvexian (Factor Xla)
Prevention and Treatment of Thrombosis

JNJ-1887
Macular Degeneration

aprocitentan
Difficult to treat hypertension

JNJ-7100
Diabetic Macular Oedema

JNJ-0795
Non-Alcoholic Steatohepatitis



CABENUVA HIV Adolescents
VAC18193 RSV Adult Vaccine
VAC52416 Multivalent ExPEC Vaccine
JNJ-3989 Combination Therapy Hepatitis B
Ultra Long-Acting HIV

VAC52150 Monovalent Ebola Virus Vaccine
REMICADE (Infliximab) COVID-19
VAC31518 Janssen COVID-19 Vaccine Pediatrics
JNJ-1802 Dengue Treatment
JNJ-0953 Influenza

VAC31518 Janssen COVID-19 Vaccine
VAC89220 HIV Px Vaccine
JNJ-3989 Hepatitis B/D Co-infection
JNJ-1802 Dengue Prophylaxis
JNJ-3283 Combination Therapy Hepatitis B



STELARA (ustekinumab)
Pediatric Juvenile Psoriatic Arthritis

TREMFYA (guselkumab)
Ulcerative Colitis Monotherapy

STELARA (ustekinumab)
Pediatric Ulcerative Colitis

nipocalimab
Warm Autoimmune Hemolytic Anemia

nipocalimab
Sjogren's Syndrome

JNJ-4804 Combination Therapy
Psoriatic Arthritis

JNJ-2113
Psoriasis

TREMFYA (guselkumab)
Crohn's Disease Subcutaneous Induction

TREMFYA (guselkumab)
Pediatric Psoriasis

STELARA (ustekinumab)
Pediatric Crohn's Disease

TREMFYA (guselkumab)
Giant Cell Arteritis

nipocalimab
Systemic lupus erythematosus

JNJ-4804 Combination Therapy
Ulcerative Colitis

JNJ-9280
Inflammatory Bowel Disease

TREMFYA (guselkumab)
Psoriatic Arthritis Structural Damage

TREMFYA (guselkumab)
Crohn's Disease

SIMPONI (golimumab)
Pediatric Ulcerative Colitis

nipocalimab
Hemolytic disease of the fetus and newborn

nipocalimab
Rheumatoid Arthritis

bermekimab
Hidradenitis Suppurativa

JNJ-4703
Rheumatoid Arthritis



seltorexant
Adjunctive treatment for major depressive disorder with insomnia symptoms

SPRAVATO (esketamine)
Suicidal Ideation Pediatric

JNJ-1813
Epilepsy

JNJ-8942
Psychiatric Disorders

nipocalimab
Generalized Myasthenia Gravis

aticaprant
Adjunctive Major Depressive Disorder

VAC20121
Alzheimer's Disease

seltorexant
Probable Alzheimer's with clinically significant agitation/aggression

JNJ-3657
Alzheimer's Disease

small molecule MGLLi
Psychiatric Disorders



niraparib

L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone

IMBRUVICA (ibrutinib)

Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (SHINE)

teclistamab (BCMA/CD3)

Relapsed refractory multiple myeloma

IMBRUVICA (ibrutinib)

Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant eligible (PERSEUS)

ERLEADA (apalutamide)

High risk prostate cancer (PROTEUS)

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed refractory multiple myeloma w/1-3 PL

RYBREVANT (amivantamab)

Frontline Non Small Cell Lung Cancer in combination with chemotherapy

IMBRUVICA (ibrutinib)

Pediatric Chronic Graft Versus Host Disease

BALVERSA (erdafitinib)

Urothelial cancer

niraparib / abiraterone acetate

M1 Metastatic Castration-Sensitive Prostate Cancer in combination with abiraterone acetate and Prednisone

IMBRUVICA (ibrutinib)

Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma; (SELENE)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible (CEPHEUS)

ERLEADA (apalutamide)

Localized prostate cancer

teclistamab (BCMA/CD3)

Multiple Myeloma 1-3PLs

TAR-200 (RIS/gemcitabine plus cetrelimab)

Muscle non invasive bladder cancer

IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW)

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed refractory multiple myeloma

amivantamab / lazertinib

Non Small Cell Lung Cancer

TAR-200 (RIS/gemcitabine plus cetrelimab)

Non-muscle invasive bladder cancer

DARZALEX (daratumumab)

Smoldering multiple myeloma (SMM3001)

CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma TNI

amivantamab / lazertinib

Non Small Cell Lung Cancer 2L

BALVERSA (erdafitinib)

Non muscle invasive bladder cancer

BALVERSA (erdafitinib)

Tumor Agnostic

erdafitinib

Intravesical Delivery System for Localized Bladder Cancer

JNJ-6617

Hematological Malignancies

JNJ-8902

Prostate Cancer

JNJ-4681

Hematological Malignancies

talquetamab (GPRC5D/CD3)

Relapsed refractory multiple myeloma

JNJ-6358

Solid Tumors

JNJ-9414

Prostate Cancer

JNJ-6420

Prostate Cancer

JNJ-1330

Colorectal Cancer

JNJ-8343

Prostate Cancer

JNJ-8780

Hematological Malignancies

JNJ-6665

Hematological Malignancies

JNJ-6633

Hematological Malignancies



UPTRAVI (selexipag)

Pediatric pulmonary arterial hypertension

OPSUMIT (macitentan)

Pediatric pulmonary arterial hypertension

macitentan

Pulmonary arterial hypertension 75mg

macitentan w/tadalafil FDC

Pulmonary arterial hypertension

macitentan

Chronic thromboembolic pulmonary hypertension 75mg

prostacyclin receptor agonist

Pulmonary Arterial Hypertension

This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Strategic Partnerships, Collaborations, and Licensing arrangements - XARELTO: Bayer; milvexian: Bristol Myers Squibb; aprocitentan: Idorsia; X-Linked Retinitis Pigmentosa (AAV-RPGR) and Achromatopsia Gene Therapies (CNGA3 and CNGB3): MeiraGTX; JNJ-7100: Exonate; JNJ-1887: Hemera Biosciences; PNPLA3: Arrowhead Pharmaceuticals; COMPLERA / EVIPLERA, ODEFSEY, SYMTUZA, PREZCOBIX / REZOLSTA FDC: Gilead Sciences; JULUCA and Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; COVID-19 vaccine: funded in part with federal funds from the U.S. Department of Health and Human Services; JNJ-3989: Arrowhead Pharmaceuticals; bacteriophage products using recombinant CRISPR/Cas3 Phage platform: Locus Biosciences; Cloudbreak antiviral conjugates (AVCs) including CD388: Cidara Therapeutics; Janssen's HIV vaccine program: IPCAVD, MHRP, HJF, the Ragon Institute, IAVI, Bill & Melinda Gates Foundation, NIAID, U.S. Military HIV Research Program, U.S. Army Medical Materiel Development Activity, MIT, Harvard, HVTN, SAMRC, Bavarian Nordic; Zika vaccine: Beth Israel Deaconess Medical Center (Harvard Medical School); ExPEC: GSK; REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113, JNJ-4238 and JNJ-5186: Protagonist Therapeutics; Tau Vaccine: AC Immune SA; JNJ-1813: Addex Pharmaceuticals; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; VELCADE: Millennium, The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO; Genmab A/S; BALVERSA: Astex Pharmaceuticals; ERLEADA: Regents of California and Memorial Slood Kettering; cilta-cel: Legend Biotech; niraparib: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); Janssen's Monovalent Ebola Vaccine: Bavarian Nordic A/S, NIAID, IMI2, EFPIA, BARDA, NIH; Filovirus multivalent vaccine: Bavarian Nordic

